Loading
How Thailand widened access to expensive targeted cancer medicines in 2007 to 2009, through a special category on the national medicines list, compulsory licences, price negotiation and company programmes, and how many more patients were treated afterwards.
The authors built timelines of access policies for two medicines on Thailand's 2013 National List of Essential Medicines, letrozole and imatinib, and three unlisted medicines for the same uses, trastuzumab, nilotinib and dasatinib, from scientific and grey literature, and used IMS Health sales data from January 2001 to December 2012 to estimate how many patients were treated before and after.
During 2007 to 2009 the government created a special category on the national list with different coverage requirements for payers and issued compulsory licences; payers negotiated prices and pooled procurement; companies expanded patient assistance programmes and lowered prices.
Thailand's special high-cost category on its essential medicines list, now called R2, dates from these years, and this paper is the measured account of what the combined measures did to the number of patients reached.
Shares Nilotinib, Dasatinib, Chronic myeloid leukaemia (CML), Imatinib.
Shares Nilotinib, Dasatinib, Chronic myeloid leukaemia (CML), Imatinib.
Shares Dasatinib, Chronic myeloid leukaemia (CML), Imatinib.
Shares Nilotinib, Dasatinib, Chronic myeloid leukaemia (CML), Imatinib.
Shares Nilotinib, Chronic myeloid leukaemia (CML).
Shares Nilotinib, Dasatinib, Chronic myeloid leukaemia (CML), Imatinib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/